References
- Shenyari I. Cutaneous leishmaniasis in Khuzestan (monograph). Khuzestan Department of Public Health Publications. 1987; 3–4, (in Persian).
- Habibi M. Challenges in treatment of cutaneous leishmaniasis (monograph). Khuzestan Department of Public Health Publications. 1987; 3–7, (in Persian).
- Report of WHO Expert Committee. Technical Report Series 701, WHO, Geneva 1984
- Martinez S, Marr J J. Allopurinol in the management of cutaneous leishmaniasis. N Engl J Med 1992; 741–4
- Saenz R F, Paz H, Berman J D. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89(2)147–55
- Ghosn S. Evaluation of sodium stibogluconate in the treatment of cutaneous leishmaniasis in Syria. Curr Med Res Opin 1979; 6(4)280–3
- Alkhawajah A, Larbi F R, Jain S, et al. Subacute toxicity of pentavalent antimony compound in rats. Hum Exp Toxicol 1992; 11(4)283–8
- Domingo P, Ferrer S, Kolle I, et al. Treatment of Indian Kala-azar with pentavalent antimony. Lancet 1995; 584–5
- Torrus D, Massa R, Roix V, et al. Meglumine antimoniate induced pancreatitis. Am J Gastroenterol 1996; 91(4)820–1, (letter)
- Gasser R A, Jr, Magill A J, Oster C N., et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18(1)83–90
- Hantson P, Leonard F D, Crutzen F MC, et al. Cytogenic observation after meglumine antimoniate therapy for visceral leishmaniasis. Pharmacotherapy 1996; 16(5)869–71
- Antezana G, Zeballos R, Mendoza C, et al. Electrocardiographic alteration during treatment of mucocutaneous leishmaniasis with meglumine antimoniate. Trans R Soc Trop Med Hyg 1992; 86(1)31–3